ARTICLE | Finance
Dynamic duo
Medicxi backs anticoagulation play SuperX, the third newco from hematology duo
February 11, 2017 2:42 AM UTC
The asset-centric model of venture investing often sees a VC working with a stable of serial entrepreneurs who are deployed to new companies when the ones they have founded or helmed are sold. But few have been as prolific in as short a time as SuperX Ltd.’s scientific co-founders CSO Jim Huntington and CMO Trevor Baglin.
Last week Medicxi backed the duo’s latest newco with an $11 million series A round mere days after co-leading a £14 million ($17.5 million) A round for the pair’s ApcinteX Ltd. with Touchstone Innovations plc (LSE:IVO). ...